Indaptus Therapeutics releases its second-quarter 2026 financial results, detailing revenue, expenses, and research progress. The biotech firm highlights advancements in its pipeline of neurodegenerative disease treatments. Management provides an operational update on clinical trials and strategic partnerships.
Indaptus Therapeutics secures a **$6 million securities purchase agreement** from investor **David E. Lazar**. The deal supports the biotech company’s funding needs as it advances its pipeline of therapeutic candidates. Lazar’s investment highlights growing confidence in Indaptus’s development-stage assets.
Indaptus Therapeutics reports third-quarter earnings exceeding analyst expectations. The company’s financial performance surpasses projections, though specific figures or drivers are not detailed in the report. Analyst coverage and a press release provide further context for investors.
Indaptus Therapeutics releases its third-quarter 2025 financial results, detailing revenue, expenses, and cash position. The biotech company also provides an operational update on its pipeline, including progress in clinical trials for its lead asset. Management highlights strategic initiatives to advance development programs while maintaining liquidity.
